We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Proteome Sciences Plc | LSE:PRM | London | Ordinary Share | GB0003104196 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.14 | 2.50 | 3.60 | - | 0.00 | 08:00:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 7.78M | 1.33M | 0.0045 | 6.98 | 9.27M |
Date | Subject | Author | Discuss |
---|---|---|---|
17/4/2024 15:54 | Much the same here.How is Mariola still in a job given 4 years of no progress,in fact she has taken the company back 10 years. | peverill | |
17/4/2024 12:18 | Radio silence on the LSE board, I note. Nothing, not even after the dire results. | barry evans | |
15/4/2024 17:54 | Hugh volume today though362 shares at 3.72p ? 9.96 gross - charges, ~ £5Don't get overwhelmed though by this serious investment: -) | goggin | |
15/4/2024 09:29 | yet anther p-tau 17 blood test hits the market Roche, Lilly Alzheimer's blood test granted FDA breakthrough device designation can someone get Pike the phone number for #patentlawyers4U (no win no fee) | elpirata | |
12/4/2024 21:18 | He wants to write it off,like the rest of us have had to do,due to his leadership and business acumen. | peverill | |
12/4/2024 16:51 | I note that cjp's loan with interest accruing is now £11.235m & prm has an mcap just over £9m | elpirata | |
12/4/2024 12:35 | normal service resumed, zilch trades, not a sausage STRONG DONT BUY | elpirata | |
11/4/2024 11:09 | The "top coins" rubbish below is nothing to do with me - I would delete it if I could I say goatherd thats a bit strong isnt it? We all know pools has a tendency to wander down the garden path but 'rubbish?' Will you be banning the avatar next? | elpirata | |
10/4/2024 15:11 | And may I ask we vote against any of these being reinstated for another 12 months.tia. | peverill | |
10/4/2024 15:08 | Should tank about 16.25. | peverill | |
10/4/2024 14:48 | I'll stick to looking at the share price and long term chart, thanks all the same. | barry evans | |
10/4/2024 14:45 | Unfortunately, you should pay far more attention, as your hatred for everything PRM completely blinds you. Proteome Sciences have stated AD license deals publicly. You can find out where yourself. STRONG BUY | wasjobber | |
10/4/2024 13:48 | Odd that they should make no mention of this in either the Profit warning or those dire results and downbeat supporting statements, no? | barry evans | |
10/4/2024 13:29 | Proteome Sciences have only recently received these important new patent grants. The area is complex and just because biomarkers are currently being used by other companies, it does not mean they won't require a license from Proteome Sciences moving forward. I think Proteome Sciences will get license deals (and associated back payments) for Alzheimers disease and cancer soon. | wasjobber | |
10/4/2024 12:43 | the olde fishing expedition bait given another outing I note our patented biomarkers may prove critical in development of novel diagnostic tests opening up additional licensing opportunities As of April 2024, there are at least eight different Alzheimer’s blood biomarker tests on the market... & prm nowhere to be seen, we've been down this alleged patents rabbit hole many times before | elpirata | |
10/4/2024 12:19 | Maeby? vbrs Michael Cera | barry evans | |
10/4/2024 12:17 | ‘Maybe’ btw. | monte1 | |
10/4/2024 12:15 | I should imagine he is feeling a right Charlie today. Randox_Girl Posts: 3 Price: 3.00 Strong Buy Good news coming 4 Apr 2024 21:39 Proteome Sciences will announce good news with their results | barry evans | |
10/4/2024 12:04 | Mabey deliberately negative, looking for a bid? | goggin | |
10/4/2024 11:24 | There are very, very few crumbs of comfort to be taken from the results. Line after line it is repeated that each and every sales sector was 'Challenging' As for the US start up, perhaps the timing couldnt have been more wrong? "It was a challenging year in our service business in 2023. As in previous years, the US is by far our most significant market in terms of biopharma companies who outsource their proteomic services to Contract Research Organisations ("CROs") such as Proteome Sciences. Unfortunately, the biopharma market especially in the US was marked by employee layoffs in 2023. According to Fierce Biotech, a company that provides news, analysis and data relating to the biotech sector, biopharma layoffs were 57% up in 2023. This has been confirmed by other Life Science provider companies in their public reporting. The significantly reduced level of financing in biopharma resulted in workforce reductions affecting 187 organisations in 2023. We were in contact and discussing projects with 38 of these that were primarily focused in proteomic pre-clinical and clinical research. Projects were either cancelled before samples were shipped, or significantly delayed pending future financing rounds. This seriously affected our ability to win business." | barry evans | |
10/4/2024 11:12 | We knew the number would be poor as it was flagged earlier, and we also knew that the expences of establishing a presence in America would be high. For myself I am pleased that we are in our biggest market. I am hopeful of the upcomibg stroke test and the real potential of Alzimers especially after the anounced reserch going on in Oxford. In addition the development of new products provides some comfort to me. | wellhonedhutch | |
10/4/2024 10:13 | Someone been on the crack pipe over the other thread. | peverill |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions